Evaluation of the Bioavailability of Pramlintide

This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.

Inclusion Criteria:

• HbA1c value between 6-12%
• BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2
• Consistent insulin regimen for 2 months prior to screening